Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.

Autor: Arguello A; Denali Therapeutics Inc., South San Francisco, CA., Mahon CS; Denali Therapeutics Inc., South San Francisco, CA., Calvert MEK; Denali Therapeutics Inc., South San Francisco, CA., Chan D; Denali Therapeutics Inc., South San Francisco, CA., Dugas JC; Denali Therapeutics Inc., South San Francisco, CA., Pizzo ME; Denali Therapeutics Inc., South San Francisco, CA., Thomsen ER; Denali Therapeutics Inc., South San Francisco, CA., Chau R; Denali Therapeutics Inc., South San Francisco, CA., Damo LA; Denali Therapeutics Inc., South San Francisco, CA., Duque J; Denali Therapeutics Inc., South San Francisco, CA., Fang M; Denali Therapeutics Inc., South San Francisco, CA., Giese T; Denali Therapeutics Inc., South San Francisco, CA., Kim DJ; Denali Therapeutics Inc., South San Francisco, CA., Liang N; Denali Therapeutics Inc., South San Francisco, CA., Nguyen HN; Denali Therapeutics Inc., South San Francisco, CA., Solanoy H; Denali Therapeutics Inc., South San Francisco, CA., Tsogtbaatar B; Denali Therapeutics Inc., South San Francisco, CA., Ullman JC; Denali Therapeutics Inc., South San Francisco, CA., Wang J; Denali Therapeutics Inc., South San Francisco, CA., Dennis MS; Denali Therapeutics Inc., South San Francisco, CA., Diaz D; Denali Therapeutics Inc., South San Francisco, CA., Gunasekaran K; Denali Therapeutics Inc., South San Francisco, CA., Henne KR; Denali Therapeutics Inc., South San Francisco, CA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA., Sanchez PE; Denali Therapeutics Inc., South San Francisco, CA., Troyer MD; Denali Therapeutics Inc., South San Francisco, CA., Harris JM; Denali Therapeutics Inc., South San Francisco, CA., Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, CA., Shan L; Denali Therapeutics Inc., South San Francisco, CA., Watts RJ; Denali Therapeutics Inc., South San Francisco, CA., Thorne RG; Denali Therapeutics Inc., South San Francisco, CA.; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN., Henry AG; Denali Therapeutics Inc., South San Francisco, CA., Kariolis MS; Denali Therapeutics Inc., South San Francisco, CA.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2022 Mar 07; Vol. 219 (3). Date of Electronic Publication: 2022 Feb 28.

CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside.

Autor: Ronaldson, Patrick T., Williams, Erica I., Betterton, Robert D., Stanton, Joshua A., Nilles, Kelsy L., Davis, Thomas P.

Publikováno v: Stroke (00392499); Jan2024, Vol. 55 Issue 1, p190-202, 13p

Ortaçağ İslâm Dünyasında Süryani Tarih Yazıcılığı.

Autor: TOMAKİN, Ahmet Yasin¹ a.y.tomakin@gmail.com

Publikováno v: Sirnak University Journal of Divinity Faculty / Sirnak Üniversitesi Ilahiyat Fakültesi Dergisi. 2017, Vol. 8 Issue 18, p233-254. 22p.

Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.

Autor: Nilsson, L. M.^1,2,3, Keller, U. B.¹, Yang, C.¹, Nilsson, J. A.^1,3, Cleveland, J. L.¹, Roussel, M. F.² martine.roussel@stjude.org

Publikováno v: Oncogene. 5/3/2007, Vol. 26 Issue 20, p2833-2839. 7p. 3 Graphs.

Immunohistological Description of Nongestational Ovarian Choriocarcinoma in Two Female Mice With Conditional Loss of Trp53 Driven by the Tie2 Promoter.

Autor: Castiglioni, V., Ghahremani, M. Farhang, Goossens, S., Maglie, M. De, Ardizzone, M., Haigh, J. J., Radaelli, E.

Publikováno v: Veterinary Pathology; Jul2015, Vol. 52 Issue 4, p752-756, 5p